the study illustrates two schools of thought common among alzheimer’s researchers: those who believe the disease cannot be diagnosed until the emergence of cognitive impairment and those, like hansson and his team, who say diagnosis can and should be made purely based on biology and what they see happening in the brain.
“you can, for example, compare our results to prostate cancer,” said rik ossenkoppele, an associate professor in translational neuroscience. “if you perform a biopsy and find cancer cells, the diagnosis will be cancer, even if the person in question has not yet developed symptoms.”
the team of researchers has watched with interest as positive results have emerged from clinical trials into lecanemab, a drug currently being administered to alzheimer’s patients.
“if we can diagnose the disease before cognitive challenges appear, we may eventually be able to use the drug to slow down the disease at a very early stage,” hansson said. “in combination with physical activity and good nutrition, one would then have a greater chance of preventing or slowing future cognitive impairment.
“however, more research is needed before treatment can be recommended for people who have not yet developed memory loss.”
alzheimer’s disease is a chronic condition that results in the slow death of neurons,
according to the alzheimer’s association. this process eventually produces symptoms of memory loss, difficulty thinking or changes in mood and behaviour. the disease is the most common cause of dementia in the world — accounting for 60 to 80 per cent of all cases — and more than 747,000 canadians are currently living with alzheimer’s or another form of dementia. roughly 65 per cent of people diagnosed with the disease after the age of 65 are women.